Welcome to our dedicated page for Ainos news (Ticker: AIMD), a resource for investors and traders seeking the latest updates and insights on Ainos stock.
Ainos, Inc. (NASDAQ: AIMD) is a dual-platform AI and biotech company whose news flow is centered on its AI Nose SmellTech platform and related AI infrastructure, alongside development of its low-dose oral interferon candidate, VELDONA. Company updates frequently highlight progress in digitizing scent into Smell ID, expanding industrial deployments, and advancing its Smell Language Model (SLM) through its subsidiary ScentAI Inc.
On this page, readers can follow AIMD news related to industrial partnerships, commercialization milestones, and strategic agreements. Recent announcements have covered distribution and deployment partnerships in semiconductor front-end manufacturing, collaborations with industrial computing and edge AI providers, and expansion of AI Nose pilots across smart factories, robotics, and healthcare environments. Ainos also issues press releases on its GICS reclassification into the technology sector, intellectual property additions, and SmellTech-as-a-Service contracts.
Investors and observers can expect news items on topics such as multi-year SmellTech-as-a-Service agreements, pilot deployments in senior care and robotics, new patents for AI Nose and digital olfaction, and updates on the company’s platform strategy to separate sensing hardware (Ainos) from AI intelligence (ScentAI). Financial result releases and associated commentary provide additional context on research and development priorities and commercialization roadmaps.
By monitoring this news feed, users gain a consolidated view of how Ainos is building its SmellTech ecosystem across semiconductors, industrial automation, robotics, and healthcare, while continuing to develop its VELDONA oral interferon program. Bookmark this page for ongoing coverage of AIMD press releases, partnership announcements, and regulatory communications.
Ainos, Inc. (OTC PINK:AIMD) announced significant early milestones in its mRNA vaccine development targeting the Delta variant of SARS-CoV-2. The company's synthetic RNA (SRNA) research is a key focus of its Preventive Medicine division. Ainos has designed a novel plasmid for universal viral gene expression suitable for extensive mRNA production. Preliminary formulations of liposome particles for mRNA delivery have been developed for efficacy testing in cell lines and animal models. Overall, Ainos aims to stimulate protective immunity against SARS-CoV-2 variants, enhancing public health response.
Ainos, Inc. (OTC PINK:AIMD) appointed Ms. Hui-Lan (Celia) Wu as its new Chief Financial Officer on August 16, 2021, succeeding Mr. Chun-Hsien Tsai, who remains the Chairman and CEO. Wu, with nearly 30 years of experience in accounting and management consulting, previously served as a partner at KPMG Taiwan. The company continues to invest in key personnel, including Lawrence Lin as Executive Vice President of Operations and John Junyong Lee as Chief Legal Counsel. Ainos focuses on rapid disease testing products, particularly for COVID-19.
Ainos, Inc. (OTC PINK:AIMD) has entered into an exclusive agreement to act as the master sales and marketing agent for the Ainos SARS-CoV-2 Antigen Rapid Test Kit in partnership with Taiwan Carbon Nano Corporation. The Taiwan Food and Drug Administration granted emergency use authorization for this test kit, which boasts smartphone tracking via QR code. The kit provides results in 15 minutes and has shown high sensitivity and specificity. Ainos aims to secure further regulatory approvals for expansion in additional markets.
Ainos, Inc. (formerly Amarillo Biosciences) announced on May 24, 2021, that the Financial Industry Regulatory Authority (FINRA) approved its name change and new ticker symbol AIMD. This change takes effect immediately, following a securities purchase transaction with Ainos, Inc. of the Cayman Islands. The company has engaged Donohoe Advisory Associates LLC to help evaluate U.S. National Securities Exchanges listing requirements. Ainos focuses on developing innovative healthcare products, including diagnostics for COVID-19 and other infections.